Last reviewed · How we verify
D-0502
D-0502 is a small molecule that targets the molecular target.
D-0502 is a small molecule that targets the molecular target. Used for Phase 3 for unspecified indication.
At a glance
| Generic name | D-0502 |
|---|---|
| Sponsor | InventisBio Co., Ltd |
| Drug class | small molecule |
| Target | unknown |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the molecular target, which results in the desired therapeutic effect. This mechanism of action is still being researched and understood.
Approved indications
- Phase 3 for unspecified indication
Common side effects
- unknown
Key clinical trials
- JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer (PHASE1, PHASE2)
- A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer (PHASE1)
- Study in Healthy Adult Female Subjects (PHASE1)
- Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects (PHASE1)
- Food Effect Study of D-0502 Tablet in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |